Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05773144 · ClinicalTrials.gov registry record · NA

Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer

A NA study of Colonic Neoplasms, sponsored by AdventHealth Translational Research Institute.

Recruiting
Registry status
NA
Development phase
219
Enrollment target
3
Study locations

NCT05773144 is a NA study of Colonic Neoplasms that is actively recruiting participants, run by AdventHealth Translational Research Institute. The registered enrollment target is 219 participants, below the 1,507-participant average among 14 other Colonic Neoplasms trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05773144, a NA study of Colonic Neoplasms, is actively recruiting participants, sponsored by AdventHealth Translational Research Institute.

RECRUITING
Registry status
NA
Development phase
219 participants
Enrollment target
3
Study locations

Study Summary

To goal of this clinical trial is to quantify the dose-response effects of aerobic exercise training compared to attention control on chemotherapy relative dose intensity in colon cancer survivors.

Conditions Studied

Interventions

  • BEHAVIORAL Aerobic exercise
  • BEHAVIORAL Progressive stretching

Study Locations (3)

California

  • Kaiser Permanente Northern California - Oakland

Florida

  • AdventHealth - Orlando

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 219 participants
Start Date 2023-06-01
Est. Completion 2027-05-01
Phase NA

What the Registry Record Tells You About NCT05773144

The ClinicalTrials.gov registry entry for NCT05773144 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 14 other Colonic Neoplasms trials with a reported enrollment target (85% lower). The listed sponsor is AdventHealth Translational Research Institute, which has 54 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Colonic Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Aerobic exercise is the first listed.

NCT05773144 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05773144 about?

NCT05773144 is a clinical study titled "Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer". To goal of this clinical trial is to quantify the dose-response effects of aerobic exercise training compared to attention control on chemotherapy relative dose intensity in colon cancer survivors.

What is the current status of trial NCT05773144?

This trial is currently recruiting. It is a NA study. The enrollment target is 219 participants. The study started on 2023-06-01. Estimated completion is 2027-05-01.

What conditions does trial NCT05773144 study?

This clinical trial studies the following conditions: Colonic Neoplasms.

What interventions are being tested in trial NCT05773144?

The interventions under investigation include: Aerobic exercise (BEHAVIORAL), Progressive stretching (BEHAVIORAL).

Who is sponsoring clinical trial NCT05773144?

This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05773144 being conducted?

This trial has 3 study locations across California, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colonic Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.